A report in The New York Times has revealed that cancer drug Avastin may not be the wonder drug it was previously believed to be. Currently Avastin, or bevacizumab, is approved by the U.S. Food and Drug Administration for treating advanced lung and breast cancer.
Dr. Leonard Saltz, a colon cancer specialist at Memorial Sloan-Kettering Cancer Center in New York told the NYT that the benefits of Avastin may be less than what was believed.
AdvertisementAvastin is costly with a year's dose racking up $100,000.
Barbara Brenner, executive director of advocacy group Breast Cancer Action feels that there is a need for public discussion before recommending Avastin for wider use.
You May Also Like